Asian Market Insights: 3 Companies Priced Below Estimated Value

As the Asian markets navigate a complex landscape of economic indicators and geopolitical tensions, investors are keenly observing opportunities that may arise from undervalued stocks. In this environment, identifying companies priced below their estimated value can offer potential advantages, especially when these stocks demonstrate strong fundamentals and resilience amid fluctuating market conditions.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Name	Current Price	Fair Value (Est)	Discount (Est)
TechMatrix (TSE:3762)	¥1978.00	¥3896.10	49.2%
TaewoongLtd (KOSDAQ:A044490)	₩37050.00	₩72394.86	48.8%
Suzhou Alton Electrical & Mechanical Industry (SZSE:301187)	CN¥29.68	CN¥59.10	49.8%
Robosense Technology (SEHK:2498)	HK$37.00	HK$73.63	49.7%
Range Intelligent Computing Technology Group (SZSE:300442)	CN¥49.96	CN¥98.99	49.5%
Q & M Dental Group (Singapore) (SGX:QC7)	SGD0.485	SGD0.97	49.8%
Matsuya R&DLtd (TSE:7317)	¥733.00	¥1436.08	49%
Japan Eyewear Holdings (TSE:5889)	¥2037.00	¥3967.11	48.7%
Cosmax (KOSE:A192820)	₩215500.00	₩418304.30	48.5%
Beijing LongRuan Technologies (SHSE:688078)	CN¥30.31	CN¥60.01	49.5%

Click here to see the full list of 280 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Let's take a closer look at a couple of our picks from the screened companies.

CanSino Biologics (SEHK:6185)

Overview: CanSino Biologics Inc. is a company based in the People's Republic of China that focuses on developing, manufacturing, and commercializing vaccines, with a market cap of HK$16.41 billion.

Operations: The company's revenue segment includes Research and Development of Vaccine Products for Human Use, generating CN¥925.24 million.

Estimated Discount To Fair Value: 15.6%

CanSino Biologics reported a significant reduction in net loss for the first half of 2025, with revenue increasing to CNY 382.33 million from CNY 303.43 million a year prior. The company is trading at HK$48.36, below its estimated fair value of HK$57.3, making it undervalued based on discounted cash flow analysis by approximately 15.6%. With expected annual revenue growth of 28.9%, CanSino's financial outlook shows potential upside despite current losses.

• In light of our recent growth report, it seems possible that CanSino Biologics' financial performance will exceed current levels.
• Unlock comprehensive insights into our analysis of CanSino Biologics stock in this financial health report.

Zanyu Technology Group (SZSE:002637)

Overview: Zanyu Technology Group Co., Ltd. operates in the research, development, manufacture, and sale of surfactants and oleo chemicals both in China and internationally, with a market cap of CN¥5.40 billion.

Operations: The company's revenue segments consist of Oil & Fat Chemical generating CN¥6.92 billion, Processing Services contributing CN¥64.79 million, and Daily Chemical Factory with revenues of CN¥5.57 billion.

Estimated Discount To Fair Value: 33.5%

Zanyu Technology Group is trading at CN¥11.73, significantly below its estimated fair value of CN¥17.64, suggesting it is undervalued based on discounted cash flow analysis. Despite a high debt level and an unstable dividend history, the company's earnings are forecast to grow 40.45% annually over the next three years, surpassing the Chinese market average. Recent financials show revenue growth from CN¥4.62 billion to CN¥6.55 billion year-on-year for H1 2025, with stable net income performance.

• Our comprehensive growth report raises the possibility that Zanyu Technology Group is poised for substantial financial growth.
• Click here and access our complete balance sheet health report to understand the dynamics of Zanyu Technology Group.

AEON Financial Service (TSE:8570)

Overview: AEON Financial Service Co., Ltd. operates through its subsidiaries to offer a range of financial services in Japan, with a market capitalization of ¥326.20 billion.

Operations: AEON Financial Service Co., Ltd. generates revenue through its subsidiaries by providing a variety of financial services in Japan.

Estimated Discount To Fair Value: 22.3%

AEON Financial Service is trading at ¥1511, over 20% below its estimated fair value of ¥1945.76, indicating it is undervalued based on discounted cash flow analysis. Earnings are projected to grow significantly at 21.23% annually, outpacing the Japanese market's average growth rate. However, a delayed earnings announcement due to accounting issues with a Vietnamese subsidiary raises concerns about transparency and operational stability despite plans for regional expansion in Asia.

• Our growth report here indicates AEON Financial Service may be poised for an improving outlook.
• Dive into the specifics of AEON Financial Service here with our thorough financial health report.

Where To Now?

• Reveal the 280 hidden gems among our Undervalued Asian Stocks Based On Cash Flows screener with a single click here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com